ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022 Final Analysis of the CLL2-GIVe Trial: Obinutuzumab, Ibrutinib, & Venetoclax in Untreated CLL With 17p Deletion/TP53 Mutation
By
ASH 2022 Conference Coverage
FEATURING
Stephan Stilgenbauer
By
ASH 2022 Conference Coverage
FEATURING
Stephan Stilgenbauer
29 views
December 22, 2022
Login to view comments.
Click here to Login
Leukemia